Ocrevus Relapse Rate
In 2017 Ocrelizumab became the first treatment to be approved for primary progressive MS PPMS a less common form in which the disease continually progresses without relapses. The average annualised relapse rate across all patients was very low 0005 and their mean change in Expanded Disability Status Scale score EDSS from baseline significantly improved from 171. Ocrevus Ocrelizumab In Rms CADTH COMMON DRUG REVIEW Clinical Review Report for Ocrevus 6 Abbreviations ARR annualized relapse rate CDEC Canadian Drug Expert Committee CDP confirmed disability progression CDI confirmed disability improvement CI confidence interval CNS central nervous system DMT disease-modifying therapy EMA European Medicines Agency. Ocrevus relapse rate . In the OPERA II trial the annualized relapse rate was 016 in the ocrelizumab group as compared with 029 in the interferon beta-1a group difference 014 annualized relapses. Treatment with Ocrevus significantly reduced the annualised relapse rate by 464 at 9